These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23841504)

  • 1. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy.
    Smith BD; Mahmoud D; Dacosta-Byfield S; Rosen VM
    Leuk Lymphoma; 2014 May; 55(5):1119-25. PubMed ID: 23841504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
    Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
    Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care utilization and mortality among elderly patients with myelodysplastic syndromes.
    Lindquist KJ; Danese MD; Mikhael J; Knopf KB; Griffiths RI
    Ann Oncol; 2011 May; 22(5):1181-1188. PubMed ID: 21041376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.
    King D; Schmidt R; Lesser M; Houk A; Salkeld E; Cogle CR
    Leuk Res; 2020 Sep; 96():106425. PubMed ID: 32702549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes.
    Ryblom H; Hast R; Hellström-Lindberg E; Winterling J; Johansson E
    Eur J Oncol Nurs; 2015 Apr; 19(2):99-106. PubMed ID: 25488465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
    DeZern AE; Binder G; Rizvi S; Corvino FA; Arikian SR; Surinach A; Lee J; Smith BD
    Leuk Lymphoma; 2017 Nov; 58(11):2649-2656. PubMed ID: 28482722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
    Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
    Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications.
    Gupta P; LeRoy SC; Luikart SD; Bateman A; Morrison VA
    Leuk Res; 1999 Oct; 23(10):953-9. PubMed ID: 10573142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity].
    Tanaka T; Kozakai T; Kitajima T; Fuse K; Kobayashi H; Ushiki T; Shibazaki Y; Moriyama M; Takizawa J; Sone H; Fuse I; Masuko M
    Rinsho Ketsueki; 2017; 58(12):2402-2405. PubMed ID: 29332874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restrictive Versus Liberal Transfusion Strategies in Myelodysplastic Syndrome and Beyond.
    Wilde L; Pan J
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):758-762. PubMed ID: 31678078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusions at home in patients with myelodysplastic syndromes.
    Niscola P; Tendas A; Giovannini M; Cupelli L; Trawinska MM; Palombi M; Scaramucci L; Brunetti GA; Perrotti A; Neri B; Efficace F; Cartoni C; de Fabritiis P; Mandelli F
    Leuk Res; 2012 Jun; 36(6):684-8. PubMed ID: 22336393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome.
    Cakar MK; Yegin ZA; Baysal NA; Altındal S; Pamukçuoğlu M; Celik B; Yenicesu I
    Transfus Apher Sci; 2013 Jun; 48(3):397-401. PubMed ID: 23619324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes.
    Moncharmont P; Quittançon E; Barday G; Benamara A;
    Vox Sang; 2019 May; 114(4):349-354. PubMed ID: 30818416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
    Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
    Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of economic costs associated with transfusion dependence in adults with MDS.
    Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
    Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.